Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease;Effetti della PGE-1 negli arteriopatici periferici al 2° stadio di Fontaine

Minerva Cardioangiologica

Volumn 51, Issue 3, 2003, Pages 311-316

  Milio, G ^a,b   Cospite, V ^a   Cospite, M ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Alprostadil; Arterial occlusive diseases; Hemodynamics; Microcirculation

Indexed keywords

BUFLOMEDIL; PENTOXIFYLLINE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BUERGER DISEASE; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODYNAMICS; HUMAN; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STRAIN GAUGE PLETHYSMOGRAPH; STRAIN GAUGE TRANSDUCER; TREADMILL EXERCISE; WALKING;

ADULT; AGED; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; VASCULAR RESISTANCE; VASODILATOR AGENTS; WALKING;

EID: 0042030868     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication: is a supervised exercise class worth while? Br Med J 1980;280:1503-6.
2. Diehm C, Kuhn A, Strauss R, Hubsch-Muller C, Kubler W. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl therapy in patients with intermittent claudication: a controlled study. VASA 1989; Suppl 28: 26-30.
3. Heidrich H, Allenberg J, Cachovan M, Creutzig A, Diehm C, Gruss J. Guideliness for therapeutic studies on peripheral arterial occlusive disease Fontaine II-IV. VASA 1992;21:339-43.
4. Scheffler P, De La Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage II b of peripheral arterial occlusive disease: the additive effects of intravenous prostaglandin E1 or intravenous pentoxyfilline during training. Circulation 1994;90:818-22.
5. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G et al. Intravenous prostaglandin E-1 versus pentoxyfilline: a randomized controlled study in patients with intemittent claudication. Proceedings of 17th World Congress of International Union of Angiology; April 3-7, 1995; London, UK. Inter Angiol 1995;14Suppl 1:280.
6. Scheffler H, De La Hamette D, Leipnitz G. Therapeutic efficacy of intravenous applied prostaglandin E1. VASA 1989; Suppl 28:19-23.
7. Simmet T, Peskar BA. Prostaglandin E1 and arterial occlusive disease: pharmacological considerations. Eur J Clin Invest. 1988;18:549-54.
8. Sinzinger H, Fitscha P. Influence of PGE-1 on in vivo accumulation of radiolabelled platelets and LDL on human arteries. VASA 1987; Suppl 17:5-10.
9. Crutchley DJ, Conanan LB, Maynard JR. Stimulation of fibrinolytic activity in human skin fibroblast by prostaglandins E1, E2 and I2. J Pharmacol Exp Ther 1982;222:544-9.
10. Ney P, Braun M, Szymanski CH, Schror K. PGE-1 and its three primary metabolites: vasoactivity and effects on human platelet and PNM function: 7th Intern Confer on Prostaglandins and related compounds; 28 May-1 June 1990; Florence, Italy. Abstract book 1990;abs 259.
11. Krone W, Klass A, Nagele H, Behnke B, Greten H. Effects of prostaglandin-E1- on low density lipoprotein receptor activity and cholesterol syntesis in freshly isolated human moncnuclear leukocytes. In: Sinzinger H, Rogatti W. Prostaglandin E1 in Atherosclerosis. Berlin, Springer Verlag 1986.p.32-8.
12. Sinzinger H, Fitscha P, Wagner O, Kaliman J, Rogatti W. Prostaglandin E1 decreases activation of arterial smooth muscle cells. Lancet, 1987;II:156-7.
13. Blume J, Klesewetter H, Ruuhmann U. Clinical and haemorheological efficacy of i.a. PGE-1 infusions in intermittent claudication: VASA 1987;Suppl 17:32-5.
14. Rudofsky G. The effect of intraarterial and intravenous prostaglandin E1 in a model of ischaemia in healthy volunteers. In: S inzinger H, Rogatti W, editors. prostaglandin E1 in Atherosclerosis. Berlin: Springer Verlag; 1986.p.49-53:
15. Brecht T, Ayaz M. Circulation parameters during intravenous and intraarterial administration of increasing doses of Prostaglandin E1 in healthy subjects. Klin Wochenschrift, 1985;63:1201-5.
16. Rudofsky G. Be einflussung der kollateralarterien durch i.a.-prostaglandin E1 infusion. VASA 1987; Suppl 20:215-7.
17. Rudofsky G. Intravenose PGE-1 infusionsbehandlung bei patienten mit arterieller verschlubkrankeit im stadium II b. In: Heidrich H, Bohme H, Rogatti W, editors. Prostaglandin E1-Wirkungen unfd therapeutiske wirksamkeit. Berlin Springerl Verlag; 1988;103-11.
18. Andriessen MPHM, Barendsen GJ, Wouda AA, De Pater L. Changes of walking distance in patients with intermittent claudication during six months intensive physical training. VASA, 1989;8:63-8.
19. Sinzinger H, Virgolini I, Fitscha P, Rauscha F, Kaliman J. Stabilization of endothelial lining and decrease in circulating endothelial cells: one mechanism underlying the clinical action of PGE-1. Br J Clin Pharmacol 1988;25:775-9.
20. Stiegler H, Rett K, Wircmary H, Leipnitz G. Metabolic effects of prostaglandin E1 on human skeletal muscle with special regard to the amino acid metabolism. VASA 1989; Suppl 28:14-8.